Skip to content

Clinical study of the pulmonary protective effect of Penehyclidine combined with parecoxib sodium in patients with combined fragile lung function undergoing general anesthesia

Clinical study of the pulmonary protective effect of Penehyclidine combined with parecoxib sodium in patients with combined fragile lung function undergoing general anesthesia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084606
Enrollment
Unknown
Registered
2024-05-21
Start date
2022-10-10
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative pulmonary function

Interventions

Pentoxifylline hydrochloride Group:Valacyclovir hydrochloride 0.5mg was given 10min before anesthesia
Parecoxib sodium group:Parecoxib sodium 40mg was given 10min before anesthesia
Blank control group:Give the same dose of saline 10 min before anesthesia
Combined drug group:Long tocopherol 0.5mg and parecoxib sodium 40mg were given respectively 10min before anesthesia

Sponsors

The Third Hospital of Hebei Medical University;Tiemenguan City People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. ASA classification I-III; 2. Age 40-85 years; 3. Receiving surgical treatment under general anesthesia; 4. Sex is not limited; 5. combined with fragile pulmonary function (moderate or above reduced pulmonary function: preoperative vital capacity (VC) < 80% of the expected value, forced expiratory volume in first second (FEV1) and forced vital capacity (FVC) ratio (FEV1%) < 70%; blood gas analysis indexes capacity (FVC) ratio (FEV1%) < 70%; blood gas analysis index (60mmHG < oxygen partial pressure < 75mmHG); patients with combined moderate or higher chronic obstructive pulmonary disease; combined chronic lung diseases such as pneumonic pneumonia, bronchial asthma, bronchiectasis, lung cancer, chronic obstructive pulmonary emphysema or pulmonary alveoli; 6. Voluntary participation and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who refused to be enrolled in this study; 2. Patients who have met the criteria for respiratory failure before surgery; 3. Patients with severe peptic ulcers, hematologic disorders; 4. Patients with severe abnormalities of cardiopulmonary, hepatic and renal functions, and severe hypertension; 5. Patients with a history of allergy to anticholinergic drugs or NSAIDs, a history of aspirin asthma and those who have taken NSAIDs 1 week before surgery; 6. Patients with intraoperative circulatory as well as organ function instability due to bleeding, allergy, etc., who need to be sent to ICU with a tube after surgery.

Design outcomes

Primary

MeasureTime frame
Blood gas analysis results;CRP;

Secondary

MeasureTime frame
Pulse Oxygen;Extubation time;Airway pressure;PACU time;Delayed extraction;Returned to ICU after surgery;

Countries

China

Contacts

Public ContactLiuPeng

The Third Hospital of Hebei Medical University/Tiemenguan City People's Hospital

liupeng2010aa@126.com+86 132 8447 3704

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026